COMPOSE Study (Neuroendocrine Tumors)

Purpose of this Study

We are doing this study to compare the study drug, lutetium-177 edotreotide, to existing standard-of-care therapies.

Who Can Participate?

Eligibility

Adults with a gastroenteropancreatic neuroendocrine tumor (GEP-NET) that is:<ul>
<li>Unresectable (cannot be surgically removed)</li>
<li>Well differentiated</li>
<li>High grade 2 or grade 3 (Ki-67 index of 15 to 55)</li>
<li>Somatostatin receptor positive (SSTR+)</li></ul>
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you choose to join this study, you will:<ul>
<li>Be assigned to get either the study drug or an existing therapy (CAPTEM, everolimus, or FOLFOX)</li>
<li>Get up to 6 IV administrations of the study drug 6-8 weeks apart (if assigned) OR take pills and/or get IV administrations of your assigned standard-of-care therapy</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Principal Investigator

Michael
Morse

Protocol Number

PRO00108718

NCT ID

NCT04919226

Phase

III

Enrollment Status

Open to Enrollment